Table 1.
Variable | Patients | AA1 | HW1 | NHW1 | Other | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | N | % | P2 | ||
Study Population | 159 | 100 | 29 | 18.2 | 96 | 60.4 | 29 | 18.2 | 5 | 3.1 | ||
Age: Mean (SD) | 56.3 | (9.3) | 55.1 | (7.4) | 57.2 | (9.4) | 55.5 | (10.5) | 50.2 | (9.2) | 0.30 | |
BMI (kg/m2) | ||||||||||||
<25 | 47 | 29.6 | 4 | 13.8 | 24 | 25.0 | 15 | 51.7 | 4 | 80.0 | 0.003 | |
25 – 29.99 | 51 | 32.1 | 7 | 24.1 | 37 | 38.5 | 6 | 20.7 | 1 | 20.0 | ||
≥30 | 61 | 38.4 | 18 | 62.1 | 35 | 36.5 | 8 | 27.6 | 0 | 0 | ||
Clinical stage | ||||||||||||
0 | 33 | 20.8 | 5 | 17.2 | 22 | 22.9 | 4 | 13.8 | 2 | 40.0 | 0.23 | |
IA–B | 79 | 49.7 | 11 | 37.9 | 51 | 53.1 | 16 | 55.2 | 1 | 20.0 | ||
IIA–IIIC | 47 | 29.6 | 13 | 44.8 | 23 | 24.0 | 9 | 31.0 | 2 | 40.0 | ||
Smoking History | ||||||||||||
Never | 108 | 67.9 | 18 | 62.1 | 8 | 70.8 | 18 | 62.1 | 4 | 80.0 | 0.53 | |
Ever | 51 | 32.1 | 11 | 37.9 | 28 | 29.2 | 11 | 37.9 | 1 | 20.0 | ||
Smoking Status | ||||||||||||
Never | 108 | 67.9 | 18 | 62.1 | 68 | 70.8 | 18 | 62.1 | 4 | 80.0 | 0.30 | |
Former | 45 | 28.3 | 8 | 27.6 | 26 | 27.1 | 10 | 34.5 | 1 | 20.0 | ||
Current | 6 | 3.8 | 3 | 10.3 | 2 | 2.1 | 1 | 3.4 | 0 | 0 | ||
Week 3 EASR grade | ||||||||||||
0 | 25 | 15.8 | 5 | 17.9 | 16 | 16.7 | 2 | 6.9 | 2 | 40.0 | 0.10 | |
1 | 125 | 79.1 | 20 | 71.4 | 78 | 81.3 | 24 | 82.8 | 3 | 60.0 | ||
2 | 8 | 5.1 | 3 | 10.7 | 2 | 2.1 | 3 | 10.3 | 0 | 0 | ||
Week 6 EASR grade | ||||||||||||
0 | 2 | 1.3 | 1 | 3.4 | 1 | 1.0 | 0 | 0 | 0 | 0 | 0.173 | |
1 | 77 | 48.4 | 12 | 41.4 | 46 | 47.9 | 15 | 51.7 | 4 | 80.0 | ||
2 | 73 | 45.9 | 12 | 41.4 | 47 | 49.0 | 13 | 44.8 | 1 | 20.0 | ||
3 | 7 | 4.4 | 4 | 13.8 | 2 | 2.1 | 1 | 3.4 | 0 | 0 | ||
Pre-RT CRP (mg/L) | ||||||||||||
< 10 | 145 | 91.2 | 24 | 82.8 | 90 | 93.8 | 27 | 93.1 | 4 | 80.0 | 0.25 | |
≥ 10 | 14 | 8.8 | 5 | 17.2 | 6 | 6.3 | 2 | 6.9 | 1 | 20.0 | ||
< 2 | 58 | 36.5 | 8 | 27.6 | 36 | 37.5 | 13 | 44.8 | 1 | 20.0 | 0.39 | |
≥ 2 | 101 | 63.5 | 21 | 72.4 | 60 | 62.5 | 16 | 55.2 | 4 | 80.0 | ||
Post-RT CRP (mg/L) | ||||||||||||
< 10 | 141 | 88.7 | 23 | 79.3 | 87 | 90.6 | 27 | 93.1 | 4 | 80.0 | 0.20 | |
≥ 10 | 18 | 11.3 | 6 | 20.7 | 9 | 9.4 | 2 | 6.9 | 1 | 20.0 | ||
< 2 | 56 | 35.2 | 7 | 24.1 | 34 | 35.4 | 13 | 44.8 | 2 | 40.0 | 0.25 | |
≥ 2 | 103 | 64.8 | 22 | 75.9 | 62 | 64.6 | 16 | 55.2 | 3 | 60.0 | ||
Post-RT- pre-RT CRP(mg/L) | ||||||||||||
<0 | 71 | 44.7 | 12 | 41.4 | 41 | 42.7 | 14 | 48.3 | 4 | 80.0 | 0.36 | |
0 | 10 | 6.3 | 0 | 0 | 8 | 8.3 | 2 | 6.9 | 0 | 0 | ||
>0 and <1 | 44 | 27.7 | 7 | 24.1 | 30 | 31.3 | 6 | 20.7 | 1 | 20.0 | ||
≥1 | 34 | 21.4 | 10 | 34.5 | 17 | 17.7 | 7 | 24.1 | 0 | 0 | ||
# of Comorbidities4 | ||||||||||||
0 | 65 | 40.9 | 6 | 20.7 | 42 | 43.8 | 14 | 48.3 | 3 | 60.0 | 0.13 | |
1 | 56 | 35.2 | 12 | 41.4 | 35 | 36.5 | 9 | 31.0 | 0 | 0 | ||
2 | 28 | 17.6 | 8 | 27.6 | 15 | 15.6 | 3 | 10.3 | 2 | 40.0 | ||
≥3 | 10 | 6.3 | 3 | 10.3 | 4 | 4.2 | 3 | 10.3 | 0 | 0 | ||
Total RT dose (Gy)5 | ||||||||||||
<60 | 33 | 20.8 | 5 | 17.2 | 18 | 18.8 | 9 | 31.0 | 1 | 20.0 | 0.31 | |
60 | 108 | 67.9 | 20 | 69.0 | 69 | 71.9 | 15 | 51.7 | 4 | 80.0 | ||
>60 | 18 | 11.3 | 4 | 13.8 | 9 | 9.4 | 5 | 17.2 | 0 | 0 | ||
Breast volume (CC) | ||||||||||||
Mean (SD) | 958 | (509) | 1358 | (647) | 905 | (437) | 808 | (408) | 587 | (251) | <0.0001 | |
Median | 864 | 1357 | 831 | 774 | 593 | |||||||
Below Median (<864) | 77 | 49.7 | 8 | 28.6 | 49 | 52.7 | 16 | 55.2 | 4 | 80.0 | 0.06 | |
Above median (≥ 864) | 78 | 50.3 | 20 | 71.4 | 44 | 47.3 | 13 | 44.8 | 1 | 20.0 |
AA, Black or African American; HW, Hispanic Whites; NHW, Non-Hispanic Whites.
Chi-square or Fisher’s exact tests excluding the other race category and missing.
Combined early adverse skin reaction (EASR) grades 0 and 1.
Sum of 11 comorbidity conditions: diabetes, hypertension, heart disease, lung disease, thyroid condition, cirrhosis liver, stroke, chronic bronchitis, hepatitis, tuberculosis, and other.
Sum of total breast and boost radiation doses; the ranged was between 50 to 66.4 Gy except for one patient at 38.5 Gy.